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The major finding of this study is that, as with procedures with
higher volumes of iodinated contrast, patients with moderate-
severe chronic kidney disease undergoing coronary angiography
have an increased, contrast-volume dependent risk of CIN. De-
spite an elevated risk (1–3) and a high incidence of CIN, ultra-low
volumes of contrast were associated with low rates of CIN. These
findings have important implications concerning the referral of a
patient with moderate-severe chronic kidney disease for diagnostic
coronary angiography. With biplane imaging, studies can be
performed with very low doses of iodinated contrast (without
prolonging procedural times or radiation exposure), suggesting this
technique may mitigate the risk of CIN in many patients at highest
risk.
Our findings of a very low incidence of CIN with ultra-low
doses of contrast are very encouraging, but some limitations of this
study need to be considered. Our study was not randomized.
While the major factor associated with CIN was contrast volume
and the major factor associated with contrast volume was the use
of biplane angiography, other factors need to be considered. The
use of the iso-osmolar nonionic contrast medium, and that the vast
majority received standard therapies of intravenous hydration and
N-acetylcysteine likely contributed to a reduction in CIN. While
patients had, on average, more than 4 serum creatinine measurements
in the week after angiography, we cannot exclude the possibility that
the peak measurement in some patients was not identified and hence
the overall incidence of CIN was underestimated.
The current findings support the use of ultra-low-dose iodin-
ated contrast facilitated by biplane angiography in patients at
increased risk for contrast nephropathy referred for coronary
angiography. Further studies will be required to assess the impact
of low-dose contrast on the incidence of contrast nephropathy.
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Letters to the Editor
Age Predicts Cancer Incidence
Better Than Statin-Induced
Low-Density Lipoprotein Level
I disagree with the data analysis in the recently published article
in the Journal suggesting an association between lower statin-
induced low-density lipoprotein (LDL) levels and increased
incidence of cancer (1). My analysis of the 8 larger and longer
trials (3 years and 1,000 patients) suggests a clear associa-
tion between increasing age and increased incidence of cancer
(Fig. 1) (r2  0.77, p  0.004, regression not corrected for
study size). Age is a known and biologically plausible risk factor
for cancer. Multivariate linear regression resulted in the follow-
ing model:
Yearly cancer incidence 
 1.103 0.012 · LDL on treatment 0.0614 · age
The overall model was significant with r2  0.83 and p  0.013.
The multivariate p value for the coefficient of age (p  0.055)
was nearly statistically significant and lower than the multivar-
Figure 1 Contrast-Induced Nephropathy
Dose-dependent association of volume of administered contrast with the inci-
dence of contrast-induced nephropathy (p  0.005 by analysis of variance).
Mean  standard deviation of contrast volume for each quartile shown in
parentheses.
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iate p value for the coefficient of LDL on treatment (p  0.26).
This model suggests that age is more predictive of cancer
incidence than LDL on treatment. Based on this analysis, we
should reconsider the assertion that statin-induced lowering of
LDL is associated with increased cancer incidence.
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Risk Associated
With Statin Treatment
Several prospective, randomized, placebo-controlled trials have
established the fundamental preventive role of statins in the
treatment of atherosclerotic disease, including coronary artery
disease, stroke, and peripheral artery disease. However, in high-
risk cohorts of elderly, hypertensive patients and patients with
heart failure, low cholesterol portends a poor prognosis (1,2). This
controversial association has been ascribed to the role of cholesterol
as a marker of incipient risk, which disappears after accounting for
the early deaths (3). In their retrospective meta-analysis of statin
users in large randomized, controlled trials, Alsheikh-Ali et al. (4)
observed an association between statin-induced lowering of low-
density lipoprotein and increased risk of cancer, and they con-
cluded that this may offset some of the benefits of statins. Their
conclusion of a relationship is most likely spurious and dependent
on an association between incipient cancer risk and attainment of
low levels of low-density lipoprotein. Unfortunately, they only
reported on the statin groups. It would have been helpful if they
excluded a similar association among the placebo groups and if
they had presented data excluding deaths within the first year after
onset of statin treatment, which may be confounders. In the
longest follow-up of any statin trial, 4S (Scandinavian Simvastatin
Survival Study) demonstrated that after 10 years there was a
nonsignificant trend toward less cancer among patients who
received simvastatin treatment during the trial period (5).
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Low Low-Density Lipoprotein
Cholesterol and Cancer Risk
The central finding in the report by Alsheikh-Ali et al. (1) was
Figure 9, which suggested a relationship between achieved low-
density lipoprotein (LDL) cholesterol and newly diagnosed can-
cers in 13 arms of statin trials. I suggest that the relationship is
confounded by age in various trials. The authors accounted for
sample size, but seemingly not for age, which is a bit surprising, as
age-adjustment is one of the most frequent procedures in epide-
miologic research. Are there some specific reasons for not doing
so? In any case, reasons are not stated.
Figure 1 Dependence of Yearly Cancer Incidence
on Age in Patients Treated With Statins
Cancer incidence was calculated from data provided in Alsheikh-Ali et al. (1).
AFCAPS  Air Force Texas Coronary Atherosclerosis Prevention Study;
ALLHAT  Antihypertensive and Lipid-Lowering Treatment to Prevent Heart
Attack Trial; CARE  Cardiac Angiography in REnally impaired patients; HPS 
Medical Research Council/British Heart Foundation Heart Protection Study;
LIPID  Long-Term Intervention With Pravastatin in Ischemic Disease Trial;
PROSPER  Prospective Study of Pravastatin in the Elderly at Risk; WOS 
West of Scotland trial; 4S  Scandinavian Simvastatin Survival Study.
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